Seegene, Inc. Names John G. Hurrell as Senior Executive Vice President

GAITHERSBURG, MD and SEOUL, KOREA--(Marketwire - January 14, 2013) - Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex molecular technologies and multiplex molecular diagnostic tests, today announced the appointment of Dr. John G. Hurrell as its new Senior Executive Vice President. In this position, Dr. Hurrell will run Seegene’s B2B business unit responsible for global licensing, OEM, and companion diagnostic deals with global top-tier healthcare players, as well as widening customer base within the clinical laboratory test market.

“We are excited to have Dr. Hurrell join Seegene’s leadership team,” said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene. “John’s distinguished track record of growing companies in the healthcare industry will be an asset as we continue to drive Seegene’s growth both organically and through strategic acquisitions.”

Most recently Dr. Hurrell was the President and General Manager of Focus Diagnostics, a subsidiary of Quest Diagnostics. At Focus Diagnostics Dr. Hurrell led the development and launch of more than 70 molecular tests and successfully gained 510(k) approvals for six products.

Prior to that Dr. Hurrell served as Vice President of Business Development at Quest Diagnostics. He also held numerous management positions at healthcare firms, including Senior Vice President and General Manager of TriPath Oncology, a subsidiary of TriPath Imaging, which was acquired by Becton, Dickinson and Company.

About Seegene
Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies -- ACP™, DPO™, READ, and qTOCE™ -- are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene aims to become one of the top five global molecular diagnostics firms by 2015 and is actively pushing ahead with a series of promising licensing deals with global top-tier healthcare players to make its qTOCE™ technology become the new gold standard.

For more information please visit www.seegene.com or call +301-762-9066.

Digg this Bookmark with del.icio.us Add to Newsvine

Technorati: multiplex diagnostics molecular diagnostics molecular diagnostics companion diagnostics